This discovery offers profound insights to clinical management as it provided a potential explanation of the mechanisms of atezolizumab (anti-PDL1) and bevacizumab (anti-VEGF) in HCC treatment and suggested the possibility of utilising oncofoetal biomarkers to individualise treatment selection. Here, VEGFA is linked to hepatocellular carcinoma.